Prognostic differences between VAP from Acinetobacter baumanii and VAP from other microorganisms
- PMID: 23905048
- PMCID: PMC3728786
Prognostic differences between VAP from Acinetobacter baumanii and VAP from other microorganisms
Abstract
Nosocomial infection, in particular pneumonia, is an important risk factor for hospital mortality and morbidity. Acinetobacter baumanii is a common multi-resistant microorganism responsible of Ventilator Associated Pneumonia (VAP). Currently Colistin is a rescue therapy for this pathogen. The purpose of this retrospective study is to compare the outcome of VAP caused by Acinetobacter baumanii and VAP from other microorganisms in critical patients. Comorbidity, prognostic scores, mortality and eradication frequency did not turn out significantly different between the two study groups. Colistin safety was tested.
Keywords: Acinetobacter baumanii; Colistin; VAP.
References
-
- Piazza O, Tufano R, Papaianni C. Le infezioni nosocomiali in terapia intensiva. 2008
-
- National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. Am J. Infect Control. 2004;32:470–85. - PubMed
-
- Health Protection Agency. Mandatory Surveillance: Mandatory Staphylococcus aureus bacteraemia surveillance scheme. http://www.hpa.org.uk/infections/topics_az/staphylo/staphylo_mandatory_s....
-
- Malacarne, et al. “Epidemiology of nosocomial infection in 125 Italian intensive care”. Minerva Anestesiologica. 2010;76:13–23. - PubMed
-
- Chastre J, et al. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165:867–903. - PubMed
LinkOut - more resources
Full Text Sources